ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

20.45
-0.81
( -3.81% )
Updated: 05:19:24

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
20.45
Bid
20.42
Offer
20.48
Volume
233,166
19.86 Day's Range 21.50
19.86 52 Week Range 47.97
Market Cap
Previous Close
21.26
Open
21.49
Last Trade
1
@
20.45
Last Trade Time
05:19:41
Financial Volume
US$ 4,820,161
VWAP
20.6727
Average Volume (3m)
546,994
Shares Outstanding
51,431,220
Dividend Yield
-
PE Ratio
-3.13
Earnings Per Share (EPS)
-6.59
Revenue
886k
Net Profit
-338.79M

About Spyre Therapeutics Inc

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Spyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRE. The last closing price for Spyre Therapeutics was US$21.26. Over the last year, Spyre Therapeutics shares have traded in a share price range of US$ 19.86 to US$ 47.97.

Spyre Therapeutics currently has 51,431,220 shares in issue. The market capitalisation of Spyre Therapeutics is US$1.09 billion. Spyre Therapeutics has a price to earnings ratio (PE ratio) of -3.13.

SYRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.59-11.241319444423.0423.319.8652345221.7140363CS
4-0.32-1.5406836783820.7724.8319.8658324622.4971CS
12-7.13-25.85206671527.5829.0619.8654699423.19028677CS
26-5.42-20.950908388125.8740.119.8655335527.10891558CS
52-3.13-13.273960983923.5847.9719.8655747029.06055057CS
1569.6489.176688251610.8147.9710.4250112928.39328193CS
2609.6489.176688251610.8147.9710.4250112928.39328193CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 20.45
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51,431,220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1.09B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 19.86 to US$ 47.97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -3.13
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 1.2k
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338.79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ONVOOrganovo Holdings Inc
US$ 1.3501
(265.88%)
318.24M
RETOReTo Eco Solutions Inc
US$ 1.1111
(88.32%)
38.95M
SLXNSilexion Therapeutics Corporation
US$ 1.16
(54.67%)
82.75M
WAFUWah Fu Education Group Ltd
US$ 2.74
(53.07%)
110.63M
LVTXLAVA Therapeutics NV
US$ 1.335
(42.02%)
17.79M
SXTCChina SXT Pharmaceuticals Inc
US$ 4.076
(-39.35%)
600.08k
YYAIConnexa Sports Technologies Inc
US$ 0.7911
(-37.71%)
4.72M
RNAZTransCode Therapeutics Inc
US$ 4.24
(-37.46%)
382.3k
ATPCAgape ATP Corporation
US$ 1.12
(-30.00%)
1.47M
BTDRBitdeer Technologies Group
US$ 9.291
(-29.08%)
12.35M
ONVOOrganovo Holdings Inc
US$ 1.3501
(265.88%)
318.24M
NVDANVIDIA Corporation
US$ 129.575
(-0.54%)
170.69M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 14.45
(-16.62%)
121.95M
WAFUWah Fu Education Group Ltd
US$ 2.74
(53.07%)
110.63M
PLTRPalantir Technologies Inc
US$ 88.16
(-2.78%)
96.74M